secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-174506
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana reports $90.1M cash, $40-45M facility impairment; positive UP421 data at 6 months
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities ~$90.1M as of July 31, 2025.
- Expects $40-45M non-cash impairment on Bothell/Seattle facilities due to sublease plans and manufacturing shift.
- Raised $29.1M net proceeds via ATM sale of 7.44M shares between April 1 and August 6, 2025.
- UP421 trial meets all endpoints: transplanted beta cells survive, produce insulin, evade immune detection at 6 months.
- Sonja Schrepfer, SVP and Head of Hypoimmune Platform, resigned to pursue other opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312525174506/0001193125-25-174506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312525174506/d36055d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer